9 studies found for:    "Rhabdomyosarcoma embryonal"
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Conditions: Neuroblastoma;   Sarcoma;   Rhabdomyosarcoma-Embryonal;   Rhabdomyosarcoma- Alveolar;   Neuroectodermal Tumors, Primitive, Peripheral
Interventions: Drug: Tumor Purged/CD25 Depleted Lymphocytes;   Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine;   Drug: rhIL-7;   Biological: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
2 Recruiting Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Conditions: Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate
3 Active, not recruiting Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Conditions: Adult Malignant Mesenchymoma;   Adult Rhabdomyosarcoma;   Childhood Alveolar Rhabdomyosarcoma;   Childhood Botryoid-Type Embryonal Rhabdomyosarcoma;   Childhood Embryonal Rhabdomyosarcoma;   Childhood Malignant Mesenchymoma;   Non-Metastatic Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Drug: Irinotecan Hydrochloride;   Biological: Dactinomycin;   Drug: Cyclophosphamide;   Drug: Vincristine Sulfate;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
4 Recruiting Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Conditions: Pleuropulmonary Blastoma;   Cystic Nephroma;   Sertoli-Leydig Cell Tumor of Ovary;   Medulloepithelioma;   Embryonal Rhabdomyosarcoma of Cervix;   Goiter;   Sarcoma;   Pineoblastoma;   Pituitary Tumors;   Wilms Tumor
Intervention:
5 Completed Biomarkers in Patients With Advanced Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Alveolar Rhabdomyosarcoma;   Childhood Embryonal Rhabdomyosarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Intervention: Other: Laboratory Biomarker Analysis
6 Completed Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Alveolar Rhabdomyosarcoma;   Childhood Embryonal Rhabdomyosarcoma;   Metastatic Childhood Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Biological: Cixutumumab;   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide;   Drug: Vincristine Sulfate Liposome
7 Unknown  Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma
Condition: Sarcoma
Interventions: Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate
8 Unknown  Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma
Condition: Sarcoma
Interventions: Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy
9 Completed Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Condition: Life Threatening Diseases
Intervention: Drug: Imatinib mesylate

Indicates status has not been verified in more than two years